Cellanome — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2020, Cellanome is a private, platform-technology company operating in the genetics and genomics sector. Its core innovation is the Cellanome R3200 Platform, an integrated system that combines live-cell imaging, single-cell transcriptomics, and programmable micro-environments (CellCages) to track cellular dynamics and interactions longitudinally. The company is pre-revenue, targeting research applications in immunology, oncology, neurobiology, and aging to accelerate therapeutic discovery and biological modeling.

ImmunologyOncologyNeurobiologyAging & Metabolic Disease

Technology Platform

The Cellanome R3200 Platform is an integrated system featuring proprietary CellCage™ technology. CellCages are 3D-printed micro-environments that isolate live cells for longitudinal tracking. The platform combines time-lapse fluorescent imaging, functional assays, and single-cell RNA sequencing on the *same* cells, generating multimodal, AI-ready datasets that link dynamic cellular behavior to molecular profiles.

Opportunities

Cellanome operates at the convergence of two large markets: single-cell genomics and live-cell imaging, addressing a clear gap for longitudinal, multimodal data.

The generation of structured, causal datasets is perfectly aligned with the growing demand for AI/ML-ready biological data to power computational models and digital twins in drug discovery.

Risk Factors

Key risks include challenging adoption of a novel, complex workflow against established single-cell methods, potential future competition from larger life science tools companies, and execution risks in seamlessly integrating hardware, biology, and software.

The platform's premium positioning may also limit its market to well-funded labs.

Competitive Landscape

Cellanome's primary competition is indirect, stemming from the use of separate technologies: high-throughput scRNA-seq platforms (10x Genomics, BD, Parse Biosciences) and high-content live-cell imaging systems (Sartorius, Molecular Devices). Its unique value proposition is the direct, longitudinal link between function and omics from the same cells, for which there are few, if any, direct commercial competitors currently.

More companies in AI / Machine Learning →More companies in United States →